Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCFinancial_Report.xls
10-Q - QUARTERLY REPORT - KERYX BIOPHARMACEUTICALS INCv318892_10q.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR8.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR5.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR6.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR7.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR2.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR4.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR1.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR3.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR12.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR11.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR17.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR16.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR15.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR10.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR18.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR21.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR14.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR23.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR22.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR13.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR20.htm
EX-31.1 - EXHIBIT 31.1 - KERYX BIOPHARMACEUTICALS INCv318892_ex31-1.htm
EX-32.1 - EXHIBIT 32.1 - KERYX BIOPHARMACEUTICALS INCv318892_ex32-1.htm
EX-31.2 - EXHIBIT 31.2 - KERYX BIOPHARMACEUTICALS INCv318892_ex31-2.htm
XML - IDEA: XBRL DOCUMENT - KERYX BIOPHARMACEUTICALS INCR9.htm
EX-32.2 - EXHIBIT 32.2 - KERYX BIOPHARMACEUTICALS INCv318892_ex32-2.htm
v2.4.0.6
Stockholders Equity - Additional Information (Detail) (USD $)
3 Months Ended 6 Months Ended 6 Months Ended 6 Months Ended 6 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Minimum
Jun. 30, 2012
Maximum
Jun. 30, 2012
Scenario 1
Jun. 30, 2012
Scenario 1
Maximum
Jun. 30, 2012
Scenario 2
Jun. 30, 2012
Scenario 3
Jun. 30, 2012
Scenario 3
Maximum
Jun. 30, 2012
Chief Executive Officer
Jun. 30, 2012
Unvested Milestone-Based Options
Employee Stock Option
Jun. 30, 2012
Unvested Milestone-Based Options
Non Employee Stock Options
Jun. 30, 2012
Restricted Stock
Dec. 31, 2011
Restricted Stock
Jun. 30, 2012
Restricted Stock
Unvested milestone-based employee awards
Jun. 30, 2012
Restricted Stock
Unvested milestone based consultant awards
Jun. 30, 2012
Restricted Stock
Milestone-based and vest upon certain corporate milestones
Jun. 30, 2012
Restricted Stock
Chief Executive Officer
Jun. 30, 2012
Stock Options
Dec. 31, 2011
Stock Options
Jun. 30, 2012
Stock Options
Milestone-based and vest upon certain corporate milestones
Stockholders Equity Note [Line Items]                                              
Number of shelf registration statements     2                                        
Shelf registration statements, offering maximum amount of common stock and warrant $ 79,000,000   $ 79,000,000                                        
Shares available for Issuance of stock option and stock-based awards 991,619   991,619                                        
Number of options                         95,000 50,000             3,777,292 3,517,000 145,000
Restricted stock granted, vesting period         3 years 4 years   3 years 1 year   3 years                        
Restricted stock issued                             1,251,430 621,581 550,000 150,000 700,000        
Number of shares of restricted stock granted                                       350,000      
Employment agreement, termination date                       2014-05-20                      
Number of shares of restricted stock to be granted             400,000   500,000 100,000                          
Minimum non-refundable cash payment from outlicensing Zerenex in foreign market other than Japan to trigger granting of 100,000 shares of restricted stock                   10,000,000                          
Gross deal value from outlicensing Zerenex in foreign market other than Japan to trigger granting of 100,000 shares of restricted stock                   50,000,000                          
Non cash compensation expense related to equity incentive granted 438,000 519,000 1,084,000 1,092,000                                      
Weighted average grant date fair value of options granted $ 1.35 $ 3.28 $ 1.73 $ 3.45                                      
Total unrecognized compensation cost related to non-vest stock options 2.0   2.0                                        
Total unrecognized compensation cost related to restricted stock                             $ 1.3                
Weighted average recognition periods for unrecognized compensation cost                             1 year 9 months 18 days           1 year 10 months 24 days